Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.59 |
| ▸ | PDE4A | P27815 | 10/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18315415 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL29689563 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL15194522 | 1.00 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL23365792 | 0.86 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL18679863 | 0.86 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL28025841 | 0.85 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL22790744 | 0.84 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4DHTR2B | |
| SCHEMBL17287625 | 0.84 | GAA (0.51) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL18652088 | 0.84 | ALDH1A1 (0.50) | PDE4BPDE4APDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL753579 | 0.83 | PDE4B (0.59) | PDE4BPDE4APDE4CPDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149003-B2 | Resolution of racemic beta-aminosulfone compounds | QUIMICA SINTETICA, S.A. (ES) | 2021-10-19 | — | — | US | disclosed |
| US-20200199072-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | QUIMICA SINTETICA, S.A. (ES) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199072-A1 | RESOLUTION OF RACEMIC BETA-AMINOSULFONE COMPOUNDS | TPMT, DHPS, SRMS | PDE4B 336/4885PDE4A 398/4885PDE4C 1190/4885 |
| US-11149003-B2 | Resolution of racemic beta-aminosulfone compounds | TPMT, DHPS, SRMS | PDE4B 336/4885PDE4A 398/4885PDE4C 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.